These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10408700)

  • 1. Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.
    Campbell MJ; Park S; Uskokovic MR; Dawson MI; Jong L; Koeffler HP
    Br J Cancer; 1999 Jan; 79(1):101-7. PubMed ID: 10408700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog.
    Campbell MJ; Park S; Uskokovic MR; Dawson MI; Koeffler HP
    Endocrinology; 1998 Apr; 139(4):1972-80. PubMed ID: 9528984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin.
    Campbell MJ; Elstner E; Holden S; Uskokovic M; Koeffler HP
    J Mol Endocrinol; 1997 Aug; 19(1):15-27. PubMed ID: 9278857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
    Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
    Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
    Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent inhibitors of proliferation of human breast cell lines.
    Koike M; Elstner E; Campbell MJ; Asou H; Uskokovic M; Tsuruoka N; Koeffler HP
    Cancer Res; 1997 Oct; 57(20):4545-50. PubMed ID: 9377567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ; Reddy GS; Koeffler HP
    J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells.
    de Vos S; Dawson MI; Holden S; Le T; Wang A; Cho SK; Chen DL; Koeffler HP
    Prostate; 1997 Jul; 32(2):115-21. PubMed ID: 9215399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
    Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines.
    de Vos S; Holden S; Heber D; Elstner E; Binderup L; Uskokovic M; Rude B; Chen DL; Le J; Cho SK; Koeffler HP
    Prostate; 1997 May; 31(2):77-83. PubMed ID: 9140119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
    Shiohara M; Uskokovic M; Hisatake J; Hisatake Y; Koike K; Komiyama A; Koeffler HP
    Cancer Res; 2001 Apr; 61(8):3361-8. PubMed ID: 11309293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells.
    Elstner E; Campbell MJ; Munker R; Shintaku P; Binderup L; Heber D; Said J; Koeffler HP
    Prostate; 1999 Aug; 40(3):141-9. PubMed ID: 10398275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
    Moffatt KA; Johannes WU; Miller GJ
    Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells.
    Polek TC; Stewart LV; Ryu EJ; Cohen MB; Allegretto EA; Weigel NL
    Endocrinology; 2003 Jan; 144(1):50-60. PubMed ID: 12488329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH; Burnstein KL
    Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3.
    Murthy S; Marcelli M; Weigel NL
    Prostate; 2003 Sep; 56(4):293-304. PubMed ID: 12858358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3.
    Liang JY; Fontana JA; Rao JN; Ordonez JV; Dawson MI; Shroot B; Wilber JF; Feng P
    Prostate; 1999 Feb; 38(3):228-36. PubMed ID: 10068347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.